Proactive Investors - Run By Investors For Investors

AusCann Group substantial shareholder lifts interest to 13.28%

Canopy Growth Corporation has exercised options valued at more than $1.535 million and now holds in excess of 42 million shares.
Cannabis leaves and medical bottles
AC8 is well advanced in delivering a strategy to develop and produce cannabinoid pharmaceuticals

AusCann Group Holdings Ltd (ASX:AC8) substantial shareholder Canopy Growth Corporation has lifted its interest in the cannabinoid pharmaceuticals developer to 13.28%.

This came about on June 10 when the Ontario, Canada-based investor exercised more than 7.677 million options at 20 cents each for consideration of in excess of $1.535 million.

Canopy, through its Australian subsidiaries - Canopy Growth Australia Pty Ltd, Canopy Growth APAC Holdings Pty Ltd and Canopy Growth Farms Australia Pty Ltd – now holds more than 42 million shares.

AusCann is targeting the treatment of chronic pain in Australia while exploring global export opportunities and expansion into additional medical areas.

READ: AusCann Group's new chief executive officer Ido Kanyon takes up role

Last month the company’s new CEO Ido Kanyon took up his new position following a comprehensive international executive search conducted by the board.

With more than 15 years of experience in pharmaceutical and medical device businesses, Kanyon has launched innovative medicines globally covering a range of commercial strategies from digital health solutions to innovative biologics.

Strong growth platform

At the time he said: “I am excited to have formally joined the team at AusCann.

“I see tremendous opportunity for AusCann to lead in the delivery of cannabis-based pharmaceutical solutions that are endorsed by physicians and address the needs of patients who are suffering from inadequately treated medical conditions.

“The company has built a strong platform on which we will continue to grow.”

READ: AusCann Group continues transition into pharmaceutical manufacturing and sales company

Kanyon added: “We have begun a comprehensive review of our strategic priorities, which will help us tailor our operating plans to ensure we deliver the positive healthcare outcomes and shareholder returns we are seeking.”

AusCann remains on track to deliver its hard-shell capsules to the market for clinical trials during 2019.

Shares today are trading at 36.5 cents, up almost 3% on yesterday’s close.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

A cannabis facility
January 10 2019
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use